My name is Ulla Wallin, Director of Clinical Affairs at Semprus BioSciences, a venture-backed biomedical company based in Cambridge, Mass., that is currently focused on applying its innovative Semprus surface technology to the vascular access space. For those of you who are planning to attend next month’s 25th annual Association for Vascular Access Scientific Meeting in San Jose, I would like to inform you that Semprus will be making our first appearance at the meeting.
Specifically, I wanted to bring to your attention that our Chief Technology Officer, Christopher Loose, Ph.D., will give a podium presentation of an abstract titled “Vascular Access Catheter with Multi-month Reduction in Microbial Adhesion and Thrombosis Formation.” The presentation, which will take place on Tuesday, October 4, in Room A3 at the San Jose Convention Center, will focus on the benefits of Semprus’ non-leaching betaine-modified catheters as per their demonstrated reduction in both microbial adhesion and thrombosis over 56-90 days of blood product exposure.
Representatives from Semprus will also be at a booth in the exhibit hall to conduct surveys on issues related to thrombotic occlusions that VA nurses must deal with. We look forward to seeing you in San Jose!